A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation
文献类型：期刊论文
| 作者 | Fu, Yun-Feng; Zhu, Yi-Na; Ni, Jia; Zhong, Xiang-Gen; Tang, Wei ; Re, Yu-Dan; Shi, Li-Ping; Wan, Jin; Yang, Yi-Fu; Yuan, Chong
|
| 刊名 | JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
 |
| 出版日期 | 2006-11 |
| 卷号 | 319期号:2页码:799-808 |
| ISSN号 | 0022-3565 |
| DOI | 10.1124/jpet.106.107185 |
| 文献子类 | Article |
| 英文摘要 | The reversible S-adenosyl-L-homocysteine hydrolase inhibitor DZ2002 [methyl 4-(adenin-9-yl)-2-hydroxybutanoate] suppresses antigen-induced-specific immune responses, particularly type 1 helper T cell (Th1)-type responses. Experimental autoimmune encephalomyelitis (EAE) is thought to be a Th1 cell-mediated inflammatory demyelinating autoimmune disease model of human multiple sclerosis (MS). In this study, we examined the effects of DZ2002 on active EAE induced by myelin oligodendrocyte glycoprotein (MOG) 35-55 in female C57BL/6 mice. Administration of DZ2002 (50 mg/kg/day i.p.) significantly reduced the incidence and severity of EAE, which was associated with the inhibition of MOG35-55-specific T cell proliferation and Th1-type cytokine production. In vitro studies also demonstrated that DZ2002 inhibited anti-CD3/28-induced naive T cell activation concomitant with the down-regulation of cyclin-dependent kinase (CDK) 4, CDK6, cyclin D3, and the up-regulation or protection of the CDK inhibitor p27. These findings highlight the fact that DZ2002 likely prevents EAE by suppressing T cell activation and suggest its utility in the treatment of MS and other Th1-mediated inflammatory diseases. |
| WOS关键词 | EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS ; COLLAGEN-INDUCED ARTHRITIS ; CENTRAL-NERVOUS-SYSTEM ; MULTIPLE-SCLEROSIS ; IN-VIVO ; REDUCTASE INHIBITOR ; RESPONSES ; IMMUNOSUPPRESSION ; ATORVASTATIN ; LYMPHOCYTES |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000241403500033 |
| 出版者 | AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/273459]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Zuo, Jian-Ping |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai, Peoples R China 3.Diazyme Labs, Div Gen Atom, San Diego, CA USA |
| 推荐引用方式 GB/T 7714 | Fu, Yun-Feng,Zhu, Yi-Na,Ni, Jia,et al. A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,2006,319(2):799-808. |
| APA | Fu, Yun-Feng.,Zhu, Yi-Na.,Ni, Jia.,Zhong, Xiang-Gen.,Tang, Wei.,...&Zuo, Jian-Ping.(2006).A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation.JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,319(2),799-808. |
| MLA | Fu, Yun-Feng,et al."A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation".JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 319.2(2006):799-808. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。